COMMUNIQUÉS West-GlobeNewswire

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
05/03/2026
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
05/03/2026
CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Amneal to Participate in Upcoming Investor Conference
05/03/2026
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following [...]
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
05/03/2026
Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of [...]
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
05/03/2026
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary safety and efficacy [...]
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
05/03/2026
GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic [...]
Calidi Biotherapeutics Announces Proposed Public Offering
05/03/2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
COSCIENS Provides Strategic Update
05/03/2026
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“ COSCIENS ” or the “ Company ”) today announced that the Company has made a strategic decision to cease funding [...]
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
05/03/2026
TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI [...]
President & CEO Letter to Shareholders
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- Dear Nova Leap Health Corp. (“Nova Leap” or the “Company”) Shareholders: [...]
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
05/03/2026
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than [...]
MediWound Files Annual Report on Form 20-F
05/03/2026
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed [...]
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
05/03/2026
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug [...]
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
05/03/2026
WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) [...]
Regeneron Announces Investor Conference Presentation
05/03/2026
TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on [...]
CooperCompanies Announces First Quarter 2026 Results
05/03/2026
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
05/03/2026
Please see enclosed pdf. Attachment 03052026_trading_in_shares_CHE
Quanta Therapeutics Presents Preclinical Data Establishing that Direct Multi-KRAS Inhibitors Retain Strong Activity Against Resistance Mechanisms Acquired from Treatment with pan-RAS Tri-Complex Inhibitors
05/03/2026
– Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasib in KRAS-mutated colorectal cancer cells – – Data support potential benefit [...]
Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics
05/03/2026
Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs) Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed from Tufts [...]

Pages